At Alloy we refer to ourselves as a biotechnology ecosystem company. We are building a network of collaborations among drug discovery teams, where knowledge and technology that can benefit the entirety of the ecosystem will be widely distributed and accessible by all. Our hope is that each new participant can make that system more vibrant and more successful, and that the connections formed by subgroups will ultimately strengthen the whole of the network.
It is with this that we are proud to announce we recently welcomed our 100th drug discovery partner into this ecosystem. It can feel self-serving to celebrate milestones such as this, but I am deeply grateful that this group of people have trusted Alloy and our vision, and I am excited by the potential treatments that are represented within these partnerships.
Like any true ecosystem, a large part of our strength lies in the diversity of our participants and the expertise they contribute based on their different backgrounds and experiences. We are grateful to have academic labs initiating new research with our humanized mouse platform, target-rich biotech companies prosecuting the full potential of their pipelines through joint ventures with us, and large pharma companies who trust us as an innovation partner to co-develop new foundational technologies that can then be accessible to all. We aim to be a welcome home for scientific entrepreneurs who otherwise feel lonely on the difficult path to discovering and developing new medicine and a trusted partner for discovery teams creating complex therapeutics.
At Alloy we believe that the challenge of transforming human health through new medicines is so vast that we need innovative, enabling companies to be around forever, and that our best chance of success comes from working together. We are building the world’s first biopharma ecosystem company with an infinite time horizon. By expanding our horizon over the infinite time frame, we cultivate an abundance mindset whereby we can allow others to take what they need in the near term, and we can take what we need to sustain our mission over the long run.
We are grateful for the first 100 partners who have joined us in this road to forever, and to our investors who believe in our conviction to generosity in the drug discovery process.
Optimistically,
Errik
Read and share this post on LinkedIn
